Latest Breaking News On - Eyepoint pharmaceuticals anat loewenstein - Page 1 : comparemela.com

The analysis of the XPLORE trial suggested XSB-001 showed biosimilarity to reference ranibizumab as assessed by BCVA improvement at 8 weeks.

Tel avivTel aviv medical centerDrug administrationEuropean medicines agencyEyepoint pharmaceuticals anat loewensteinEyepoint pharmaceuticalsAnat loewensteinTel aviv medicalEarly treatment diabetic retinopathy scoreUnited states